Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuropeptide Y (NPY).

David A Groneberg1, Gert Folkerts, Christian Peiser

  • 1Division of Allergy Research, Department of Pediatric Pneumology and Immunology, Charité School of Medicine, Free University and Humboldt-University, Berlin, Germany. david.groneberg@charite.de

Pulmonary Pharmacology & Therapeutics
|June 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrograde Access via Direct Puncture of the Occluded Segment in Complex Femoropopliteal Chronic Total Occlusions.

JACC. Cardiovascular interventions·2026
Same author

Pain Relief During Recanalization of Chronic Femoropopliteal Artery Occlusions With Use of a Crossing Catheter.

JACC. Case reports·2025
Same author

Optimization of ribosome profiling in plants including structural analysis of rRNA fragments.

Plant methods·2024
Same author

Interrelations of managing position with person-environment fit of gender-role orientation, and burnout.

Journal of occupational medicine and toxicology (London, England)·2024
Same author

Tuning Charge-Transfer States by Interface Electric Fields.

ACS applied materials & interfaces·2024
Same author

Randomized Trial Comparing a Stent-Avoiding With a Stent-Preferred Strategy in Complex Femoropopliteal Lesions.

JACC. Cardiovascular interventions·2024
Same journal

Brain-Derived Neurotrophic Factor (BDNF) Signaling in Respiratory Disease: Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications.

Pulmonary pharmacology & therapeutics·2026
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Neuropeptide Y (NPY) influences immune responses and is elevated in asthma exacerbations. While its role in central nervous system disorders is studied, its potential in treating pulmonary inflammation is emerging, offering future airway nerve modulation strategies.

Area of Science:

  • Immunology
  • Neuroscience
  • Pulmonology

Background:

  • Neuropeptides, including neuropeptide Y (NPY), are implicated in inflammatory disease pathogenesis.
  • NPY is a 36-amino acid neuropeptide involved in regulating physiological and pathophysiological processes across multiple systems.
  • Elevated serum NPY levels correlate with asthma exacerbations, though airway nerve density remains unchanged in inflammatory airway diseases.

Purpose of the Study:

  • To explore the role of neuropeptide Y (NPY) in the pathogenesis of inflammatory diseases, particularly in the context of pulmonary disorders.
  • To investigate the immunomodulatory effects of NPY on cellular and humoral immune functions.
  • To assess the potential of NPY-targeting therapies for pulmonary inflammatory conditions.

Main Methods:

Related Experiment Videos

  • Review of existing literature on NPY's role in inflammation and immune function.
  • Analysis of NPY's effects on immune cell distribution, T helper cell differentiation, mediator release, and natural killer cell activation.
  • Consideration of available selective receptor antagonists, agonists, and gene-depleted animal models.

Main Results:

  • NPY significantly influences immune cell distribution, T helper cell differentiation, mediator release, and natural killer cell activation.
  • NPY acts as an immunomodulator, affecting the actions of other neurotransmitters.
  • The complex pulmonary effects of NPY have previously limited therapeutic exploration for lung inflammation.

Conclusions:

  • Neuropeptide Y (NPY) demonstrates significant immunomodulatory functions relevant to inflammatory diseases.
  • Despite complex pulmonary effects, the availability of specific receptor modulators and genetic models opens avenues for NPY-based therapeutic strategies in airway nerve modulation for pulmonary inflammatory disorders.